Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices

Life Sciences

Volumn 80, Issue 14, 2007, Pages 1327-1334

  Leite, Elaine Amaral ^a   Grabe Guimarães, Andrea ^a   Guimarães, Homero Nogueira ^b   Machado Coelho, George Luiz Lins ^a   Barratt, Gillian ^c   Mosqueira, Vanessa C F ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIV PARIS SUD   (France)

Author keywords

Cardiotoxicity; Drug carriers; Halofantrine; Lipophilic drug; Nanocapsules; QT interval prolongation

Indexed keywords

DRUG VEHICLE; HALOFANTRINE; NANOCAPSULE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENCAPSULATION; HYPOTENSION; LD 50; LETHAL DOSE; MALARIA; MALE; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; QT INTERVAL; QT PROLONGATION; RAT;

MUS; RATTUS; RATTUS NORVEGICUS;

EID: 33847334258     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.12.019     Document Type: Article

References (30)

1. Abernethy D.R., Wesche D.L., Barbey J.T., Ohrt C., Mohanty S., Pezzullo J.C., and Schuster B.G. Stereoselective halofantrine disposition an effect: concentration-related QTc prolongation. British Journal of Pharmacology 51 3 (2001) 231-237
2. Barratt G.M. Colloidal drug carriers: achievements and perspectives. Cellular and Molecular Life Sciences 60 (2003) 21-37
3. Batey A.J., Lightbown I.D., Lambert J.P., Edwards G., and Coker S.J. Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetized guinea-pigs. British Journal of Pharmacology 122 3 (1997) 563-569
4. Brocks D.R., and Toni J.W. Pharmacokinetics of halofantrine in the rats: stereoselectivity and interspecies comparisons. Biopharmaceutics and Drug Disposition 20 3 (1999) 165-169
5. Brocks D.R., and Wasan K.M. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. Journal of Pharmaceutical Sciences 91 8 (2002) 1817-1826
6. Bryson H.M., and Goa K.L. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 43 20 (1992) 236-258
7. Crumb W., and Cavero I. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharmaceutical Science and Technology Today 2 7 (1999) 270-280
8. Fessi H., Puisieux F., Devissaguet J.P., Ammoury N., and Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics 55 (1989) R1-R4
9. Greenwood B.M., Bojang K., Whitty C.J.M., and Targett G.A.T. Malaria. Lancet 365 9469 (2005) 1487-1498
10. Guerin P.J., Olliaro P., Nosten F., Druilhe P., Laxminarayan R., Binka F., Kilama W.L., Ford N., and White N.J. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infectious Diseases 2 9 (2002) 564-573
11. Humberstone A.J., Porter C.J.H., and Charman W.N. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. Journal of Pharmaceutical Sciences 85 5 (1996) 525-529
12. Karbwang J., and Bangchang K.N. Clinical pharmacokinetics of halofantrine. Drug Disposition 27 2 (1994) 104-119
13. Krishna S., Ter Kuile F., Supanaranond W., Pukrittayakamee S., Teja-Isavadharm P., Kyle D., and White N.J. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. British Journal of Clinical Pharmacology 36 6 (1993) 585-591
14. Lasic D.D. Novel applications of liposomes. Trends in Biotechnology 16 7 (1998) 307-321
15. Lemoine D., François C., Kedzierewicz F., Preat V., Hoffman M., and Maincent P. Stability study of nanoparticles of poly(ε-caprolactone), poly(d,l-lactide) and poly(d,l-lactide-co-glycolide). Biomaterials 17 (1996) 2191-2197
16. Lightbown I.D., Lambert J.P., Edwards G., and Coker S.J. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. British Journal of Pharmacology 132 1 (2001) 197-204
17. Matson P.A., Luby S.P., Redd S.C., Rolka H.R., and Meriwether R.A. Cardiac effects of standard-dose halofantrine therapy. American Journal of Tropical Medicine and Hygiene 54 3 (1996) 229-231
18. Mberu E.K., and Muhia D.K. Measurement of halofantrine and its major metabolite desbutylhalofantrine in plasma and blood by high-performance liquid chromatography: a new methodology. Journal of Chromatography 581 1 (1992) 156-160
19. Mosqueira V.C.F., Legrand P., Gulik A., Bourdon O., Gref R., Labarre D., and Barratt G. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22 (2001) 2967-2979
20. Mosqueira V.C.F., Loiseau P.M., Bories C., Legrand P., Devissaguet J.P., and Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrobial Agents and Chemotherapy 48 4 (2004) 1222-1228
21. Mosqueira V.C.F., Legrand P., and Barratt G. Surface-modified and conventional nanocapsules as novel formulations for parenteral delivery of halofantrine. Journal of Nanoscience and Nanotechnology 6 9-10 (2006) 3193-3202
22. Nosten F., ter Kuile F.O., Luxemburger C., Woodrow C., Kyle D.E., Chongsuphajaisiddhi T., and White N.J. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341 8852 (1993) 1054-1056
23. Olivier C., Rizk C., Zhang D., and Jacqz-Aigrain E. Long QTc interval complicating halofantrine therapy in 2 children with Plasmodium falciparum malaria. Archives de Pediatrie 6 9 (1999) 966-970
24. Porter C.J.H., and Charman W.N. Uptake of drugs into the intestinal lymphatics after oral administration. Advanced Drug Delivery Reviews 25 1 (1997) 71-89
25. Porter C.J.H., Charman S.A., and Charman W.N. Lymphatic transport of halofantrine in the triple-cannulated anaesthetized rat model: effect of lipid vehicle dispersion. Journal of Pharmaceutical Sciences 85 4 (1996) 351-356
26. ter Kuile F.O., Dolan G., Nosten F., Edstein M.D., Luxemburger C., Phaipun L., Chongsuphajaisiddhi T., Webster H.K., and White N.J. Halofantrine versus mefloquine in the treatment of multi drug-resistant falciparum malaria. Lancet 341 8852 (1993) 1044-1049
27. Touze J.-E., Heno P., Fourcade L., Deharo J.-C., Thomas G., Bohan S., Paule P., Riviere P., Kouassi E., and Buguet A. The effects of antimalarial drugs on ventricular repolarization. American Journal of Tropical Medicine and Hygiene 67 1 (2002) 54-60
28. Warrell D.A., Molyneux M., and Beales P.F. Severe and complicated malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 84 2 (1990) 1-65
29. Wesche D.L., Schuster B.G., Wang W.X., and Woosley R.L. Mechanism of cardiotoxicity of halofantrine. Clinical Pharmacology and Therapeutics 67 5 (2000) 521-529
30. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., and Meshnick S.R. Epidemiology of drug-resistant Malaria. Lancet Infectious Disease 2 4 (2002) 209-218